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A B S T R A C TObjectives: The article takes a three-dimensional approach (triangu-
lation) in defining international pricing policy for pharmaceuticals
using cost-effectiveness analysis (CEA), willingness-to-pay (WTP)
analysis, and ability-to-pay (ATP) analysis. It attempts to find a
balance between the various economic methods of which some focus
on effectiveness while others are geared toward incorporating equity
in the equation.Methods: A critical review of the first two established
economic methods and their ability to evaluate not only ‘‘efficacy’’ but
also ‘‘fairness’’ in pricing decisions identifies a gap in the latter.
Therefore, a third analytic method is presented that measures the
ATP based on a country’s score in the human development index of
the United Nations Development Program for 120 countries. This
approach allows practicing differential pricing among and within
countries. To refine this equity-driven pricing concept, two additional
parameters can be added to the model: the Oxford ‘‘Multidimensional
Poverty Index’’ and the ‘‘Out-of-Pocket’’ or ‘‘Self Pay’’ health expendi-
ture as reported by the World Bank. Results: There is no hierarchy
between the above three pricing methods. Because one methodsee front matter Copyright & 2013, International
r Inc.
.1016/j.vhri.2013.03.001
st: The authors have indicated that they have no
es@telenet.be.
ondence to: Edith Maes, Maastricht School of Manaprovides further insight into the other, however, it is recommended
to start with CEA followed by WTP analysis. These types of analysis
are closely linked in that the first provides the CE ratio for the
compound investigated and the other sets the anticipated ceiling
threshold of the payer’s WTP (in a particular country). The ATP
method provides a supplementary ‘‘equity’’ check and facilitates the
process of equity-based differential pricing. Conclusions: A third
method should be used in conjunction with the standard CEA and
WTP analysis that measures the ATP with the human development
index as yardstick to provide sustainable and equitable access to
medicines. We recommend that ATP analysis becomes an additional
practice in policy decision making and in defining international
pricing strategies for pharmaceuticals.
Keywords: ability-to-pay, access to medicines, equity, pharmaceutical
pricing.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Providers of health technology are increasingly urged to give
payers insight into the associated costs and benefits, and
demonstrate value for money. This necessitates the use of
cost-effectiveness analysis (CEA) in defining strategies that
support pricing and reimbursement decisions. Although CE is
an important criterion, it does not provide a complete picture. A
good health policy and related pricing strategy must not only
aim to be efficient but should also ensure equitable access to
medicines.
To fulfill the requirements of health technology assessment
(HTA) agencies and reimbursement committees in an increasing
number of countries, this requires not only generating data that
prove clinical efficiency but also CE. The premise of CEA is that it
helps policymakers and executives make decisions by setting a
maximum cost threshold for a benefit outcome, often expressed
as quality-adjusted life-year (QALY) gained. Reimbursement is
granted if the incremental cost-effectiveness ratio (ICER) falls
within an acceptable range where there is debate about its cutoff
point. CE methods, however, provide an incomplete pictureespecially when they are conducted from an institutional per-
spective. In CEA, the efficiency-driven outcome is measured
against a standard that reflects the economic considerations of
the health system as a whole more than the willingness to pay
(WTP) of patients and citizens.
This has led to a search on how to incorporate a patient’s or
society’s WTP for new and existing health technologies. WTP/
QALY assessments are often based on contingent valuation
techniques. They are based on a hypothetical market that uses
the price an individual is willing to pay to obtain a beneficial
intervention. However, the estimation of WTP is subject to
considerable variability. The challenge is to avoid biases in
surveying populations that due to government and insurance
coverage may underestimate the preparedness to pay. Hence, the
WTP/QALY ratios derived from specific patient populations may
not accurately reflect the attitudes of society. The WTP/QALY
obtained through data describing human behavior or preferences
(utilities) not only yields disparate results, but the process of
aggregating utility outcomes is also not firmly grounded in
theory. Last but not the least, WTP for improved health is
influenced by income and standards of living.Society for Pharmacoeconomics and Outcomes Research (ISPOR).
conflicts of interest with regard to the content of this article.
gement, P.O. Box 1203, 6201 BE Maastricht, The Netherlands.
Fig. 1 – International pricing policy framework and process.
ATP, ability to pay; CEA, cost-effectiveness analysis; WTP,
willingness to pay.
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proportionality by means of purchasing power parity (PPP) meas-
ured at either the national level or the household level. The
method is based on the human development index (HDI) and
deemed relevant especially for a global market confronted with
disparity in the ability to pay (ATP) between countries and
between population segments. This ATP method has been pre-
sented as a poster at the ISPOR 5th Asia-Pacific Conference in
Taipei, Taiwan. In a subsequent workshop, the merits of using
these methods in parallel were highlighted: CEA, WTP, and ATP
(Fig. 1).Methods
A critical review of the ability of the CEA and WTP methods was
done to evaluate not only ‘‘efficacy’’ but also ‘‘fairness’’ in pricing
decisions. To further explore the latter, a third analytic method is
introduced that measures the ATP based on a country’s score in
the HDI (database of 120 countries). The values of the equity
index thus obtained are plotted in a nonlinear curve. The ATP/
HDI method permits the practice of differential pricing among
and within countries. To accommodate the latter, two supple-
mental parameters are added: the Oxford ‘‘Multidimensional
Poverty Index’’ (MPI) and the ‘‘Out-of-Pocket’’ (OOP) or ‘‘Self Pay’’
health expenditure as reported annually by the World Bank. By
multiplying the ATP/HDI with either both or one of these addi-
tional factors, the position of a country’s price index on the
nonlinear ‘‘equity’’ curve is expected to vary by country. Thus, the
indices MPI and OOP are used as an overlay of the HDI-based
‘‘equitable pricing curve’’ in countries that combine high poverty
and lack of health insurance coverage.Fig. 2 – Cost-effectiveness and policy decisions. ICER,
incremental cost-effectiveness ratio.Results
Method 1—CEA
Decisions regarding reimbursement and allocation of funds
within the health care budget are being influenced by the results
of CEA in an increasing number of countries. The term CE has
become synonymous with health economic evaluation and has
been used to demonstrate the extent to which interventions
measure up to what can be considered value for money [1].
The average CE ratio may provide useful information about
the overall affordability of an intervention. It is the net cost of a
strategy divided by the total number of health outcomes gained.
It is often more useful, however, to examine the efficiency of one
strategy relative to the other. This is done by calculating ICERs. Tobe able to compare interventions and capture their value, the
numerator in the ICER must be expressed as a ‘‘single’’ outcome,
and is therefore indicated in ‘‘natural’’ units (e.g., deaths avoided,
or life-years gained). Nowadays, the preferential method for
capturing health benefits is QALYs, which measures the health
gained as a combination of the duration of life (years) and the
health-related quality of life. When using QALY as the outcome
measure, the ICER represents the ratio of incremental costs per
QALY gained. The usage of QALYs as a standard measure for
measuring health outcome in CE studies should strictly speaking
be called cost-utility. Cost-utility analysis, however, can be
considered a special case of CEA, and the two terms are used
interchangeably.
The result of the calculated ICER outcome can be visualized
on a CE plane consisting of four quadrants [2] (Fig. 2). The y-axis
usually captures the difference in intervention costs (less or more
expensive), and the x-axis describes the difference in health
effects. Outcomes positioned in quadrant I (upper-right) are more
effective and more expensive, those in quadrant II (lower-right)
are more effective and less expensive, those in quadrant III
(lower-left) are less effective and less expensive, and those in
quadrant IV (upper-left) are less effective and more expensive. In
the latter case, when the new treatment is more expensive than
the current treatment but does not lead to significant health
gains, most policymakers may decide that this new treatment
does not represent value for money. Conversely, if the new
technology is less costly but more effective than the current
comparator, the new intervention is described as dominant. The
difficulty lies in assessing new technologies with an ICER that
would position them in the upper-right quadrant where the new
treatment is found cost-effective but the WTP may reach a
threshold beyond which payers are likely not to adopt the
product. In other words, there is a threshold or ceiling ratio at
which point the new product is considered no longer cost-
effective. This threshold represented by the diagonal line indi-
cates the maximum WTP [3].
To summarize, CE ratios are an important criterion in health
policy decisions. Using CEA (and even cost-utility analysis) alone,
however, may not capture all elements needed to make informed
decisions on budget allocation and do not tell whether there is a
willingness to adopt the new drug, vaccine, or health technology.
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As stated above, to measure the WTP per QALY gained, the ICER
must be compared with a ‘‘threshold’’ or ‘‘ceiling’’ value. Inter-
ventions with an ICER below this threshold may be considered
for funding, whereas those with an ICER above the threshold
tend not to be. Because of this standardized approach in
measuring health outcomes, a comparison is subsequently
possible between countries, for example, with regard to their
WTP/QALY outcome.
Without explicitly defining such a WTP threshold value, CE
has limitations as a decision-making tool, because it would lack a
systematic and universally recognizable decision criterion.
Recent literature has seen a lively debate on implicit and explicit
CE threshold(s), although without reaching consensus on the
nature or height of an appropriate monetary value of a QALY. At
this moment, various institutions and governmental bodies have
adopted threshold values in the process of optimizing the
allocation of health care resources, albeit sometimes implicitly
and inconsistently.
How much money exactly should a payer be prepared to pay
for a gain of one QALY in the population? The acceptable ranges
of the monetary value of a QALY used in such decision making
appear to be broad. Setting explicit thresholds, however, may
offer a range of theoretical advantages. It would, for instance,
make the policy decision process more transparent and consis-
tent. But health care decision making is undeniably politically
sensitive. In addition, decision makers are not necessarily econ-
omists, and are reluctant to base their decisions on a single
summary measure alone [4]. A ‘‘hard’’ threshold approach dic-
tates that results expressed, for example, as $/QALY are taken
prima facie and become the sole decision criterion. In contrast,
adopting a ‘‘soft’’ threshold makes room for considering other
preferences. With this approach, the acceptability criterion does
not lead to automatic acceptance or rejection but informs
decision makers [5]. Instead of a single figure, a threshold range
with lower and upper boundaries would be preferred. Interven-
tions below the lower boundary will usually be accepted and
made available; those above the upper level will usually be
rejected, while the in-between outcomes fall in the zone of
increasing discomfort as the cost goes ‘‘higher and higher’’ [5,6].
This means that reimbursement of interventions falling between
the lower and upper boundaries will be judged predominantly
upon additional criteria.
Yet, the WTP/QALY measure is not entirely satisfactory from a
theoretical and empirical viewpoint. There appears to be no
theoretical basis for one unique WTP/ QALY threshold [7].
Another criticism to be dealt with relates to the fact that WTP/
QALY does not fully take into consideration aspects of equity, and
may therefore lead to biases related to an individual’s age and
income level. When eliciting preferences among the young and
poor, for example, WTP/QALY is likely to be very low. However, for
the old and rich, WTP/QALY may be significantly higher [7]. It is
hard to predict the overall effect of income from data in the
literature, but the relationship is likely to be nonlinear. A study
that measured preferences in three patient populations—using
standard gamble, time trade-off, visual analog scale, and WTP to
subsequently calculate WTP/QALY ratios—found that a natural
log transformation of income may be the best predictor of WTP/
QALY [8].
In conclusion, the WTP/QALY is an important method for
measuring value for money in health care. Nonetheless, the
method fails to capture a number of factors that are potentially
important and captures other ones with varying degrees of
sensitivity. In spite of these hurdles, it is important to continue
research in this area and work toward a higher level of trans-
parency in societal decision making.Another method to guide international pricing decisions may
be the analysis of the ATP at the macroeconomic level (nations),
or at the microeconomic level for population-defined market
segments. Especially if used in conjunction with differential
pricing, less affluent populations may be served at concessionary
prices. In light of the least developed countries remaining poor in
the foreseeable future, and the emerging economies increasingly
being able to share at least part of the pharmaceutical invest-
ment, what is a ‘‘fair’’ pricing strategy? Drug developers have
traditionally relied on high-income countries to recoup the ever-
increasing research and investment costs of development of new
medicines. Despite the fact that the inherent societal value of
pharmaceutical compounds can be high within low- and middle-
income countries, there is a natural tendency for free riding and
price referencing is rife, which, in turn, triggers a convergence
toward the lowest denominator. The following section describes
how the HDI introduces proportionality in this pricing process
and aims at balancing public policy and corporate strategy. We
argue that HDI-related benchmarking provides a ‘‘just’’ key of
allocating costs across buyers, although this consideration must
be combined with the societal value of the compound. Hence, the
societal value assessment by means of CEA and WTP remains the
bedrock of the analysis.
Method 3—ATP Analysis
In this section, we examine how a country’s gross domestic
product and living standards as they are captured in the HDI may
function as a proxy measure of ‘‘real wealth’’ and form a basis for
equitable, differential pricing between countries (whereas further
intracountry differential pricing necessitates the supplementary
use of household income and health care system indices).
One of the first proposals recommending using gross domes-
tic product (GDP) as a yardstick in setting CE thresholds can be
found in the report of the Commission on Macroeconomics and
Health, commissioned by the World Health Organization [9]. The
report suggests that interventions costing less than three times
GDP per capita for each disability-adjusted life-year (not neces-
sarily QALY) averted would represent good value for money.
Although this is still used as a rule of thumb, more sophisticated
approaches have been developed to establish CE thresholds.
Nevertheless, the appeal of the GDP method is that it uses an
objective national benchmark that is directly related to the
affordability criterion. The concept of trying a national threshold
to some type of economic objective benchmark is reportedly
adaptable to QALYs [5]. As explained in the second section,
methods based on WTP/QALY are not perfect either. Acknowl-
edging the fact that different countries spent different amounts
of their GDP on health care, would it not be more straightforward
instead of the WTP to measure the ATP?
We propose to use a combination of GDP-related ‘‘macro-
economic’’ parameters with ‘‘microeconomic’’ value-based pric-
ing methods. Instead of using GDP, however, a more refined direct
measure of a nation’s income is recommended, that is, the PPP-
adjusted gross national income per capita. In our view, an even
more complete measure of wealth and economic development
would be to use the HDI altogether [10]. Both are income-related
indices and are based on large population surveys, made publicly
available and updated annually by the World Bank and the United
Nations Development Program, respectively. The HDI is a more
comprehensive metric, and functions as a comparative yardstick
that measures a nation’s social and economic development; it
contains a log-based GDP formula (which can be replaced by
gross national income-PPP [see Fig. 3]). At the outset about 10
years ago, the HDI concept exclusively focused on the economic
output of a country, but nowadays it applies a more holistic
approach by including besides the standard of living, other
Fig. 3 – Pricing using HDI- and GNI-based indexes. GNI, gross national income; HDI, human development index; PPP,
purchasing power parity.
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literacy rate, and education (see Fig. 3). This in modern econom-
ics more accurately reflects a nation’s ‘‘real wealth’’ and also in
the spirit of the ‘‘human capital theory’’ indicates that at times of
advanced science and technology being the engines of socio-
economic progress, children and adults who are well educated
and trained will determine economic progress, not only in
industrialized countries but also in the developing and emerging
economies.
We propose to use the HDI curve as the basis for determining
price discounts taking as anchor point one of the countries with
the high(est) gross national income per capita at PPP reported, for
example, the United States. This then acts as a value-based
pricing benchmark from which to start calculating equitable
prices in other countries (for which such evidence-based data
are not always available). Alternatively, this benchmark value can
be based on a basket of Organisation for Economic Co-OperationFig. 4 – Trend of equitable discounts in peand Development (OECD) countries in which value-based pricing is
being practiced. In this context, the HDI serves as a price index that
varies between 0% and 100%, whereas the market price takes into
account the intrinsic value of the new or existing drug. The
resulting equity curve is the graphic representation of the concept
of a price index calculated on the basis of a country’s national
income multiplied by product value. Each graph is product specific
and reflects the situation in a select number of countries or in all
(120 countries), hence providing an overview among countries in
which the drug is or will be launched. Countries are ranked on the
x-axis according to their national income, with the poorest coun-
tries to the left and the richest to the right. The ratio of wealth
inversely reflects the theoretical discount rate that can be applied to
each country compared with a high-income reference country. The
steepest discounts are reserved for the countries with the lowest
income. Over time, as economies will grow, and economic con-
vergence is gradually taking place, especially in Brazil, Russia, India,riod 2010-2050 (selection of countries).
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low- and middle-income countries are expected to decrease as the
country’s wealth increases. This trend is shown in Figure 4.
As a result, pharmaceutical companies can compare the
actual sales prices for existing products or predicted sales prices
for new products against the equity standard following the HDI
philosophy as described above. The result can be calculated and
displayed in two formats: a bubble chart and a histogram. The
bubble chart graphically shows a product’s price level (position
on the y-axis) by country as well as the volume sold in each
country during a particular year (reflected by the diameter of the
bubble for that country), and plots these empirical data against
the HDI-based equitable pricing curve (blue). The nonlinear
regression connecting the sales input data gives an idea of how
the empirical pricing curve (green) compares to the theoretical
equitable curve, or deviates from it (as described in Fig. 5).
To derive conclusions, the deviations can be highlighted in a
bar chart highlighting prices that differ from the theoretical
equitable curve (which depends on the margins tolerated) (Fig. 6,
Table 1). If the real sales price (position of the bubble on the y-axis
for a particular country) matches the theoretical equitable curve,
the ratio or index of real prices versus the theoretical standard for
that country is 1 (which alternatively can be set at 100%).
To summarize, we recommend using the ATP method as an
additional tool in international pricing decisions, and we have
demonstrated that this makes sense from a societal fairness point
of view. The concept of adjusting prices to buying power matches
differential pricing theory, which, in turn, is grounded in Ramsey
pricing theory [11]. Ramsey pricing (also known as differential or
tiered pricing), and its application to pharmaceuticals, means that
prices are kept low for low-income market segments with high
demand elasticity, and high prices designed to recover R&D costs
are charged to high-income market segments with lower demand
elasticity [12–14].
The ATP/HDI model was initially designed to support interna-
tional pricing decisions. However, it can be extended by incorpo-
rating intracountry pricing variables. The bridging can be done by
fitting in additional socioeconomic parameters. In our view, two
parameters are of paramount importance in intercountry as well
as intracountry-tiered pricing, and hence could be included intoFig. 5 – ATP method applied to a globally marketed medicine. AT
power parity.an expanded ATP-based model. We opted to include the Oxford
MPI and the OOP or Self Pay health expenditures reported by
country and updated annually by the World Bank. These addi-
tional indices, MPI and OOP, can be used as an overlay of the
original ATP/HDI-based ‘‘equitable pricing curve.’’ By multiplying
the HDI for a particular nation with either both or one of these
additional factors, the position of that country’s price index on the
logarithmic ATP/HDI-based equity curve turns out to be lower to a
degree that is likely to significantly vary by country. As a result, the
ATP/HDI equity curve is no longer continuous but includes discrete
variables that add an additional country-specific dimension to the
analysis. In theory, and within this wider equity context, the
bandwidth of any country may be revised further downward and
as such this ‘‘relief’’ factor determines the price range. In practice,
the MPI and OOP indices as published are reported only for low-
and middle-income countries. Based on these data, further price
concessions may be contemplated to overcome the health system
and insurance barriers in specific countries.
Finally, pharmaceutical pricing nowadays may be influenced by
risk sharing and refund agreements between supplier and insurer.
This has led to a variety of performance-based risk-sharing
strategies. Various innovative schemes have been described in
the literature, and the jury is out on whether these bilateral
arrangements offer a sustainable modus operandi [15]. Their
existence, however, does not take away the attractiveness and
even necessity to design and use equity-based pricing models as
described above. Such models are useful to conduct ex ante pricing
analysis before commercial launch albeit any product postlaunch
analysis will have to be adjusted for alleged risk-sharing ‘‘biases’’
that nonetheless can be justified on grounds of enhanced market
access. In this case, the expanded ATP method is expected to offer
a key learning to stakeholders about whether or not such risk-
sharing or price/volume arrangements have a beneficial effect on
the access to medicines and sustainability of the transaction.Conclusions
We have outlined a process for using three economic methods in
conjunction (CEA, WTP analysis, and ATP analysis) to develop anP, ability to pay; GNI, gross national income; PPP, purchasing
Fig. 6 – ATP index per country versus equitable pricing standard. ATP, ability to pay.
VA L U E I N H E A LT H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 1 6 0 – 1 6 6 165evidence-based pricing and reimbursement strategy that is not
only based on delivering proof of efficiency and CE but that also
takes equity considerations into account.
The objective was to develop a strategy that provides the
maximum possible access to new and existing medicines by cover-
ing virtually all citizens and patients across different economiesTable 1 – Summary of calculated ATP index values: HDI-
Country GNI pc, PPP
(international $)
(2010)
GNI
index
Product
actual
price (US $)
Pr
equ
pric
USA 47,120 1.000 705.40 7
Canada 37,280 0.962 523.56 6
France 34,440 0.949 611.69 6
Germany 38,140 0.966 695.53 6
Italy 31,130 0.933 710.01 6
UK 36,590 0.959 481.38 6
Spain 31,640 0.935 590.32 6
Russia 19,190 0.854 494.10 6
Turkey 15,180 0.816 532.15 5
Brazil 10,920 0.762 680.00 5
Colombia 9,000 0.731 423.53 5
Japan 34,780 0.951 775.51 6
South
Korea
29,010 0.921 540.54 6
India 3,560 0.580 175.00 4
China 7,570 0.703 200.00 4
ATP, ability to pay; GNI, gross national income; HDI, human developmenregardless of their means while at the same time providing a return
on investment to innovators and manufacturers to continue inves-
ting in developing new products that address unmet medical needs.
We recommend using all three methods. In other words, there
is no one or two methods that are preferred while the third is
not needed. Each viewpoint and associated methodology addsbased nonlinear model.
oduct
itable
e (US $)
Actual
price
index
Equitable
price
index
Difference actual price
index vs. equitable
price index
05.40 100 100 100
78.56 74 96 77
69.48 87 95 91
81.17 99 97 102
57.90 101 93 108
76.41 68 96 71
59.76 84 94 89
02.45 70 85 82
75.59 75 82 92
37.84 96 76 126
15.68 60 73 82
70.60 110 95 116
49.81 77 92 83
09.39 25 58 43
95.85 28 70 40
t index; PPP, purchasing power parity.
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underpinning decision making with regard to access and pricing.
Although there is no clear hierarchy between the methods, the
approach that we recommend is to build the triangulation
process in a stepwise manner. Because one method provides
further insight into the other, it is recommended to start with
CEA followed by WTP analysis. These types of analyses are
closely linked in that the first provides the CE ratio for the
compound investigated and the other sets the anticipated
ceiling threshold of payer’s WTP (in a particular country). The
ATP method then provides a supplementary equity-driven
assessment by incorporating macroeconomic parameters and
Ramsey pricing. Although this is the sequence of analysis
recommended, the ATP can, if need be, replace the previous
methods for strategic exercise purposes because it can be
applied without conducting a full pharmacoeconomic analysis
in each and every country (provided of course that the societal
value has been established in a number of key countries from
which positions in other countries can be extrapolated). While
the ATP model can be used to support pricing decisions world-
wide, or a particular region, we expect it to be very useful in Asia
Pacific due to the high discrepancies in socioeconomic develop-
ment Table 1.
Source of financial support: Funding for this project was
provided by Janssen, a division of Johnson & Johnson Pte Ltd.
The study design, collection, analysis, and interpretation of data,
as well as writing and submitting the article for publication were
not contingent upon the sponsor’s approval or censorship of the
manuscript. The views expressed in this article are those of the
authors and not the organizations they work for.
R E F E R E N C E S[1] Walker S, Sculpher M, Drummond M. The methods of cost-
effectiveness analysis to inform decisions about the use of health careinterventions and programs. In: Glied S, Smith P, eds., Oxford Handbook
of Health Economics. Oxford: Oxford University Press, 2011:733-58.
[2] Black W. A graphical representation of cost-effectiveness. Med Decis
Making 1990;10:212–4.
[3] Morris S, Devlin N, Parkin D, Spencer A. Principles of economic
evaluation in health care. In: Morris S, Devlin N, Parkin D, Spencer A,
eds., Economic Analysis in Health Care (2nd ed.). Chichester: John
Wiley & Sons, 2012:232-50.
[4] Zwart-van Rijkom J, Leufkens H, Busschbach J, et al. Differences in
attitudes, knowledge and use of economic evaluations in decision-
making in The Netherlands: the Dutch results from the EUROMET
project. PharmacoEconomics 2000;18:149–60.
[5] Eichler H, Kong S, Gerth W, et al. Use of cost-effectiveness analysis in
health-care resource allocation decision-making: how are cost-
effectiveness thresholds expected to emerge? Value Health
2004;7:518–28.
[6] Towse A, Pritchard C, Devlin N. Cost-effectiveness Thresholds:
Economic and Ethical Issues. London: King’s Fund and Office of Health
Economics, 2002.
[7] Gyrd-Hansen D. Looking for willingness to pay (WTP) threshold for a
QALY: does it make sense? Presented at: ISPOR 9th Annual European
Congress, October 31, 2006, Copenhagen, Denmark.
[8] King J, Tsevat J, Lave J, Roberts M. Willingness to pay for a quality-
adjusted life year: implications for societal health care resource
allocation. Med Decis Making 2005;25:667–77.
[9] WHO. Commission on Macroeconomics and Health. Macroeconomics
and Health: Investing in Health for Economic Development. Report of
the Commission on Macroeconomics and Health. Geneva: World
Health Organization, 2001.
[10] United Nations Development Program. Human Development Report
2010: The Real Wealth of Nations. New York: Pallgrave Macmillan, 2010.
[11] Ramsey F. A contribution to the theory of taxation. Econ J 1927;37:47–61.
[12] Danzon P, Towse A. Differential pricing for pharmaceuticals:
reconciling access, R&D and patents. Int J Health Care Finance Econ
2003;3:183–205.
[13] Yadav P. Differential Pricing for Pharmaceuticals 2010. UK Department
for International Development. Available from: http://www.dfid.gov.uk/
Documents/publications1/prd/diff-pcing-pharma.pdf.
[14] Daems R, Maes E, Ramani S. Global framework for differential pricing
of pharmaceuticals. Working Paper, 2011-054, United Nations
University and Maastricht University, UNU-MERIT Institute,
Netherlands, October 18, 2011.
[15] Towse A, Garrison L. Can’t get no satisfaction? Will pay for
performance help? Toward an economic framework for understanding
performance-based risk-sharing agreements for innovative medical
products. PharmacoEconomics 2010;28:93–102.
